Abnormal expression of SREBP1 is correlated with tumor progression in differentiated thyroid cancer, esophageal squamous cell carcinoma, glioblastoma, and ovarian cancer (Cheng et al., 2015; Huang et al., 2019; Koizume et al., 2019; Li et al., 2020b). Here, SREBF1 is linked to neoplasm.